111 related articles for article (PubMed ID: 2945699)
1. Pituitary, ovarian and endometrial effects of graded doses of medroxyprogesterone acetate administered on cycle days 7 to 10.
Zalányi S; Aedo AR; Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1986 Jun; 33(6):567-78. PubMed ID: 2945699
[TBL] [Abstract][Full Text] [Related]
2. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
Shumin X; Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
[TBL] [Abstract][Full Text] [Related]
3. Pituitary, ovarian and endometrial effects of 300 micrograms norethisterone and 30 micrograms levonorgestrel administered on cycle days 7 to 10.
Landgren BM; Dada O; Aedo AR; Johannisson E; Diczfalusy E
Contraception; 1990 Jun; 41(6):569-81. PubMed ID: 2113848
[TBL] [Abstract][Full Text] [Related]
4. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
5. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
Lan PT; Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
[TBL] [Abstract][Full Text] [Related]
6. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
7. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
8. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase.
Gemzell-Danielsson K; Svalander P; Swahn ML; Johannisson E; Bygdeman M
Hum Reprod; 1994 Dec; 9(12):2398-404. PubMed ID: 7714164
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations.
Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1985 May; 31(5):453-69. PubMed ID: 4028723
[TBL] [Abstract][Full Text] [Related]
11. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
12. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
13. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
14. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
15. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
[TBL] [Abstract][Full Text] [Related]
16. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
17. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
Kumari GI; Das RP; Madoiya KK; Jain AK; Roy S
Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
[TBL] [Abstract][Full Text] [Related]
19. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
[TBL] [Abstract][Full Text] [Related]
20. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses.
Wikström A; Green B; Johansson ED
Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
